Irha News English: The Federation of Asian Biotech Associations (FABA) presents a Cutting-edge Workshop on “Artificial Intelligence for Pharma & Biotech in Collaboration with Science Gurus and the University of Hyderabad scheduled on December 11-16, 2023. The day commences with enlightening opening remarks by Prof. P. Reddanna, the Executive President of FABA, setting the tone for the event. A welcome address extended by Dr. Jagath Reddy Junutula, Science Gurus and Dr. Bindu Madav Reddy from the University of Hyderabad.
The first speaker Dr. Krishnan Nandabalan, the esteemed President and CEO of InveniAI, delivered a compelling talk focusing on the pivotal theme “Artificial Intelligence for Pharma and Biotech – From Hype to Reality”. During his talk, with profound insights and expertise, Dr. Nandabalan shed light on the ever-evolving landscape of healthcare, the integration of Artificial Intelligence and Machine Learning (AI/ML) is proving to be transformative. One notable application of AI is seen in Generative AI models like ChatGPT, revolutionizing scientific research across various fronts. From Drug Discovery processes to Molecular design and synthesis, biological data interpretation, and the evolution of computational chemistry, Generative AI is paving the way for innovation. Dr. K. Nandabalan, also emphasized that a shift towards more in-silico work and reduced wet lab experimentation holds promise. This approach not only minimizes the use of reagents and animal testing but also mitigates the risk of false positives, markinga significant advancement in research methodology. He also highlights various applications of AI ranging from innovating target and drug discovery to pre-IND development, clinical development, drug manufacturing, and post-marketing surveillance. Dr. K. Nandabalan concluded with a poignant note on the convergence of human ingenuity and creativity driving innovation. As AI continues to make its mark, the future promises even more groundbreaking applications in the fields of pharmaceuticals and biotechnology.
Following the next Speaker Dr. Sunu Engineer, iSPIRT, provided the insightful keynote address on “Why Does Intelligence Need Data? Building the AI Nation”. Dr Sunu highlighted that in the dynamic landscape of technological advancements, the year 2023 is witnessing a paradigm shift with ML models emerging as the catalyst for the most significant value unlock. These meticulously curated datasets serve as the foundation for building models that, in turn, facilitate the generation of new and innovative content. The applications of ML models extend across various domains, with a particular emphasis on accurate diagnosis and personalized medicine. He said that recognizing the critical importance of data in this process, there is an urgent need for the safe and secure collection of information, aligned with principles of consent, purpose limitation, and privacy. A regulatory framework addressing the risks associated with both the development and deployment of these models is deemed imperative.
Dr. Sunu further focused on the three essential pillars of protection in this arena identified as data privacy, model validation, and prevention of monopolistic practices. The talk also touched upon the envisioned timeline for the techno-legal regulation governing data sharing. Dr. Sunu’s talk concluded with a visionary outlook emphasizing the necessity for a regulatory framework that supports ecosystem growth. This includes the establishment of regulated and open data markets, and the validation of data models and applications with assurance of safety and secure.
The day proceeded with the third Speaker, Dr. Vasudeva Varma, principal research Scientist, Brane Enterprises, who delivered an insightful lecture on “Role of Gen AI and Large Language Models in Healthcare” Dr. Varma highlighted that the frontier of artificial intelligence, the speaker commenced with an exploration of Generative AI (Gen AI) and Large Language Models (LLMs) in the context of intelligence and advanced AI applications. The session delved into the fundamentals of Gen AI, elucidating the various types of Gen AI models and their intricacies concerning input and output dynamics. Further Dr. Varma emphasized the healthcare applications of Generative AI are evolving rapidly, ranging from chatbots for patients and interactive note-taking to augmented procedures, grounded radiology reports, bedside decision support, and text-to-protein generation. He also highlighted personalized diagnosis, diagnostic assistance, doctor-patient communication, and the creation of patient/ population digital twins illustrating the transformative potential of Generative AI in healthcare. Further, Dr Varma concluded that the adoption of Generative AI in healthcare might encounter hurdles due to concerns related to transparency, safety, ethics, and accountability. Despite these challenges, potential applications, and the need for ongoing exploration and responsible integration of Generative AI in healthcare settings.
The last speaker of the day Dr. Luca Emili, Founder and CEO of InSilicoTrials, talked about “Applications, Modeling, & Simulation for Pharma and Life Sciences”. Dr. Luca emphasized that Revolutionizing Drug and Medical Device Development, In Silico Technology, takes center stage by addressing the current challenges in developing new products within the Pharma and MedTech industries. Additionally, In Silico Trials unveiled the transformative potential and innovative approach that leverages the power of simulation solutions and a cutting-edge simulation platform, providing accessible and reliable solutions to the complex landscape of pharmaceutical and MedTech development. Dr. Luca shed light on the inherent challenges faced in the development of computational models, emphasizing the multitude of elements involved. In discussing the advancements brought about in silico trials, he highlighted a staggering 99% reduction in time, catapulting the process of bringing products to market at unprecedented speed. The talk highlighted the pivotal role of modeling and simulation in supporting pharmaceutical companies, with in silico trials at the forefront of this technological evolution. By harnessing the potential of AI, these simulations are revolutionizing pharmaceutical research, offering a glimpse into a future where innovation is accelerated, and time-to-market is dramatically reduced. In silico technology emerges as a game-changer, promising efficiency, reliability, and accessibility in the pursuit of advancing drug and medical device development for the betterment of healthcare worldwide.
For further details may kindly contact Dr. Bindu Madav Reddy on email: [email protected] and his mobile no. 88972 48519
.